Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide

Journal of Clinical Pharmacology

Volumn 51, Issue 6, 2011, Pages 951-955

  Kapitza, Christoph ^a   Zdravkovic, Milan ^b   Zijlstra, Eric ^a   Segel, Stine ^b   Heise, Tim ^a   Flint, Anne ^b  

^a PROFIL Institut für Stoffwechselforschung   (Germany)

^b NOVO NORDISK A S   (Denmark)

Author keywords

DPP IV; exenatide; glucagon like peptide 1; incretin; Type 2 diabetes mellitus

Indexed keywords

LIRAGLUTIDE;

ABDOMEN; ADULT; AREA UNDER THE CURVE; ARM; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; HYPOGLYCEMIA; INJECTION SITE; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; PHARMACODYNAMICS; RANDOMIZED CONTROLLED TRIAL; THIGH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED;

EID: 79955845067     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010374474     Document Type: Article

References (17)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. 1987 ; 2: 1300-1304 (Pubitemid 17156636)
2. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 ; 101: 515-520 (Pubitemid 28084232)
3. Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology. 1994 ; 107: 1848-1855 (Pubitemid 24357644)
4. Tourrel C, Bailbe D, Lacorne M, Meile MJ, Kergoat M, Portha B. Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. Diabetes. 2002 ; 51: 1443-1452 (Pubitemid 34826610)
5. Tourrel C, Bailbe D, Meile MJ, Kergoat M, Portha B. Glucagon-like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin- treated newborn rats resulting in persistently improved glucose homeostasis at adult age. Diabetes. 2001 ; 50: 1562-1570 (Pubitemid 33639596)
6. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998 ; 47: 1663-1670 (Pubitemid 28476238)
7. Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995 ; 80: 952-927
8. Rachman J, Barrow BA, Levy JL, Turner RC. Near-normalisation of diurnal glucose concentrations administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM. Diabetologia. 1997 ; 40: 205-211 (Pubitemid 27060294)
9. Agersø H, Jensen LB, Elbrønd B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia. 2002 ; 45: 195-202 (Pubitemid 34208381)
10. Elbrønd B, Jakobsen G, Larsen S, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care. 2002 ; 25: 1398-1404 (Pubitemid 41071152)
11. Knudsen LB, Nielsen PF, Huusfeldt PO, et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem. 2000 ; 43: 1664-1669 (Pubitemid 30304999)
12. Harder H, Nielsen L, Thi TD, Astrup A. The effect of liraglutide, a long-acting glucagon-like peptide 1 derivative, on glycemic control, body composition, and 24-h energy expenditure in patients with type 2 diabetes. Diabetes Care. 2004 ; 27: 1915-1921 (Pubitemid 38989232)
13. Degn KB, Juhl CB, Sturis J, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes. 2004 ; 53: 1187-1194 (Pubitemid 38569002)
14. Senn S Statistical Issues in Drug Development. 2 nd ed. Chichester, UK: Wiley ; 2007 :
15. Clauson PG, Linde B. Absorption of rapid-acting insulin in obese and nonobese NIDDM patients. Diabetes Care. 1995 ; 18: 986-991
16. Frid A, Linde B. Intraregional differences in the absorption of unmodified insulin from the abdominal wall. Diabet Med. 1992 ; 9: 236-239
17. Vora JP, Burch A, Peters JR, Owens DR. Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry. Diabetes Care. 1992 ; 15: 1484-1493